Investigating future therapies
Our scientists are committed to developing new genomic medicines for patients with serious diseases that are not well managed with current treatments, where our suite of technologies may be able to make a difference.
Developing genomic medicines requires years of laboratory research and clinical testing to evaluate safety and efficacy. Volunteers who enroll in clinical trials help Sangamo researchers understand the potential benefits and risks of these investigational therapies in humans. Investigational therapies must pass through various phases of clinical research before they can be approved for medicinal use.
Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines. Please visit the links below to learn more about our clinical trials.
CURRENTLY RECRUITING PARTICIPANTS
Pfizer is conducting a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male participants with moderately severe or severe hemophilia A. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT04370054.
We are conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of ST-920 gene therapy in Fabry disease. Please visit our study website at https://staarclinicalstudy.com or https://clinicaltrials.gov/ct2/show/NCT04046224.
For more information, check out the STAAR Clinical Trial Factsheet to learn about Fabry disease, ST-920 and the study design.
Sanofi is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and efficacy of BIVV003 ex vivo gene-edited cell therapy in severe Sickle Cell Disease. For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT03653247
ONGOING STUDIES, NOT CURRENTLY RECRUITING